Cold-adapted, live attenuated influenza vaccine

Expert Review of Vaccines

Volumn 3, Issue 2, 2004, Pages 131-139

  Glezen, W Paul ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cold adapted; Epidemic control; FluMist ; Influenza vaccine; Live attenuated influenza vaccine

Indexed keywords

ANTIBIOTIC AGENT; ANTIVIRUS AGENT; INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE; TRIPLE VACCINE;

BRAIN DISEASE; CAUSE OF DEATH; CLINICAL TRIAL; DISEASE TRANSMISSION; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; FEVER; HEALTH CARE PERSONNEL; HUMAN; IMMUNE DEFICIENCY; INFLUENZA; INFLUENZA VIRUS; INFLUENZA VIRUS A; MYALGIA; MYOCARDITIS; MYOSITIS; NONHUMAN; NOSE CONGESTION; OTITIS MEDIA; PERICARDITIS; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; REVIEW; RHINORRHEA; SINGLE DRUG DOSE; VOMITING;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; HUMANS; IMMUNITY, HERD; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS; VACCINES, ATTENUATED;

EID: 1842685790     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.2.131     Document Type: Review

References (49)

1. Maassab HF. Adaptation and growth characteristics of influenza virus at 25°q 45C. Nature 213, 612-14 (1967).
2. Maassab HF, DeBorde DC. Development and characterization of cold-adapted virus for use as live virus vaccines. Vaccine 3, 355-369 (1985).
3. Keitel WA, Piedra PA. Live cold-adapted reassortant influenza vaccines (USA). In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Ed), Blackwell Science, Oxford, UK, 373-390 (1998). The authors summarize studies of the live attenuated influenza vaccine sponsored by NIAID, NIH, USA that led to development for licensure.
4. Centers for Disease Control and Prevention. Using live, attenuated influenza vaccine for prevention and control of influenza: supplemental recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 52(RR-13), 1-8 (2003).
5. Piedra PA, Glezen WP, Mbawuike I et al. Studies on reactogenicity and immunogenicity of attenuated bivalent cold recombinant influenza type A (CRA) and inactivated trivalent influenza virus (TI) vaccines in infants and young children. Vaccine 11, 718-724 (1993).
6. Glezen WP. Emerging infections: pandemic influenza. Epidemiol. Rev. 18, 64-76 (1996). This paper provides the rationale for universal immunization of children.
7. Thompson WW, Shay DK, Weintraub E et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 289, 179-186 (2003).
8. Centers for Disease Control and Prevention. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 52(RR-8), 1-34 (2003).
9. Centers for Disease Control and Prevention. Update: influenza activity - United States, December 21, 2003-January 3, 2004. MMWR 52, 1288-1290 (2004).
10. Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 283, 499-505 (2000).
11. Neuzil KM, Nellen BG, Wright PF, Mitchell EF, Griffin MR. The effect of influenza on hospitalizations, out-patient visits and courses of antibiotics in children. N. Engl J. Med. 342, 225-231 (2000). This paper describes the impact of influenza on healthy children.
12. Izurieta HS, Thompson WW, Karmarz P et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N. Engl J. Med. 342, 232-239 (2000).
13. Centers for Disease Control and Prevention. Severe morbidity and mortality associated with influenza in children and young adults. MMWR 52, 837-840 (2003).
14. Centers for Disease Control and Prevention. Update: influenza-associated deaths reported among children aged <18 years - United States, 2003-2004 influenza season. MMWR 52, 1286-1288 (2004).
15. Chiu SS, Tse CYC, Lau YL, Peiris M. Influenza A infection is an important cause of febrile seizures. Pediatrics 108(4), E63 (2001).
16. Glezen WP, Taber LH, Frank AL, Gruber WC, Piedra PA. Influenza virus infections in infants. Pediatr. Infect. Dis. J. 16, 1065-1068 (1997).
17. Neuzil KM, Hohlbein C, Zhu Y. Illness among schoolchildren during influenza season. Arch. Pediatr. Adolesc. Med. 156, 986-991 (2002).
18. O'Brien KL, Walters MI, Sellman J et al. Severe pneumococcal pneumonia in previously healthy children: the role of preceding influenza infection. Clin. Infect. Dis. 30, 784-789 (2000).
19. Robinson P, Taylor K, Nolan T. Risk-factors for meningococcal disease in Victoria, Australia, in 1997. Epidemiol. Infect. 127, 261-268 (2001).
20. Bernstein T, Brilli R, Jacobs B. Is bacterial tracheitis changing? A 14 month experience in a pediatric intensive care unit. Clin. Infect. Dis. 27, 458-462 (1998).
21. Glezen WP. Prevention of acute otitis media by prophylaxis and treatment of influenza virus infections. Vaccine 9, S56-S58 (2001).
22. Glezen WP. Consideration of the risk of influenza in children and indications for prophylaxis. Rev. Infect. Dis. 2, 408-420 (1980).
23. Reichert TA, Sugaya N, Fedson DS et al. The Japanese experience with vaccinating school children against influenza. N. Engl. J. Med. 344, 889-896 (2001). Evaluation of the Japanese schoolchildren program of influenza immunizations provides proof of concept for universal influenza immunization of children.
24. Reichert TA. The Japanese program of vaccination of school children against influenza: implications for control of the disease. Semin. Pediatr. Infect. Dis. 13, 104-111 (2002).
25. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of school children. J. Infect. Dis. 122, 16-25 (1970).
26. Hurwitz ES, Haber M, Chang A et al. Effectiveness of influenza vaccination of daycare children in reducing influenza-related morbidity among household contacts. JAMA 284, 1677-1682 (2000).
27. Rudenko LG, Slepushkin AN, Monto AS et al. Efficacy of live attenuated and inactivated influenza vaccines in school children and their unvaccinated contacts in Novgorod, Russia. J. Infect. Dis. 168, 881-887 (1993).
28. Belshe RB, Mendelman PM, Treanor J et aL The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N. Engl. J. Med. 338, 1405-1412 (1998).
29. Oya A, Nerome K. Experience with mass vaccination of young age groups with inactivated vaccines. In: Options for the Control of Influenza. Kendal AP, Patriarcha PA (Eds), Alan R. Liss, Inc., NY, USA, 183-192 (1986).
30. Hurwitz ES, Haber M, Chang A et al. Studies of the 1996-1997 inactivated influenza vaccine among children attending day care: immunologic response, protection against infection and clinical effectiveness. J. Infect. Dis. 182, 1218-1221 (2000).
31. Couch RB, Quarles JM, Cate TR, Zahradnik JM. Clinical trials with live, cold-reassortant influenza virus vaccines. In: Optionsfor the Control of Influenza. Kendal AP, Patriarcha PA (Eds), Alan R. Liss, Inc., NY, USA 223-241 (1986).
32. Keitel WA, Couch RB, Quarles JM et al. Trivalent attenuated cold-adapted influenza virus vaccine: reduced viral shedding and serum antibody responses in susceptible adults. J. Infect. Dis. 167, 305-11 (1993).
33. Mendelman PM, Cordova J, Iksung C. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine 19, 2221-2226 (2001).
34. King JC, Lagos R, Bernstein DI et al. Safety and immunogencity of low and high doses of trivalent live cold-adapted influenza vaccine administered intranasally as drops or spray to healthy children. J. Infect. Dis. 177, 1394-1397 (1998).
35. Longini IM Jr, Halloran ME, Nizam A et al. Estimation of the efficacy of live, attenuated influenza vaccine from a 2 year, multi-center vaccine trial: implications for influenza control. Vaccine 18, 899-906 (2000). Efficacy of CAIV-T in young children is reviewed and implications for control of epidemic influenza explored.
36. Belshe RB, Gruber WC, Mendelman PM et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J. Pediatr. 136, 168-175 (2000).
37. Belshe RB, Gruber WC, Mendelman PM et al. Correlates of immune protection induced by live, attenuated cold-adapted, trivalent, intranasal influenza virus vaccine. J. Infect. Dis. 181, 1133-1137 (2000).
38. Treanor JJ, Kotloff K, Betts RF et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild type influenza A(H1N1), A(H3N2) and B viruses. Vaccine 18, 899-906 (2000).
39. Nichol KL, Mendelman PM, Mallon KP et al. Effectiveness of live, attenuated intranasal influenza virus vaccine in health, working adults. JAMA 282, 137-144 (1999).
40. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine 21, 2207-2217 (2003).
41. Gaglani MJ, Piedra PA, Herschler GB et al. Direct and total effectiveness of the intranasal, live attenuated, trivalent cold-adapted influenza virus vaccine against the 2000-2001 influenza A(H1N1) and B epidemic in healthy children. Arch. Pediatr. Adolosc. Med. 158, 65-73 (2004).
42. Halloran ME, Longini IM Jr, Gaglani MJ et al. Estimating efficacy of trivalent, cold-adapted, influenza virus vaccine (CAIV-T) against influenza A(H1N1) and B using surveillance cultures. Am. J. Epidemiol. 158, 305-311(2003). Demonstrates the use of selective influenza surveillance of a subset of participants in Phase IV trials to calculate adjusted efficacy.
43. Monto AS. Invited commentary: use of selective viral cultures to adjust nonvirologic end points in studies of influenza vaccine efficacy. Am. J. Epidemiol. 158, 312-315 (2003).
44. Piedra PA, Gaglani MJ, Herschler G et al. Safety and effectiveness of the trivalent, cold-adapted influenza (CAIV-T) in children. In: Options for the Control of Influenza IV, Osterhaus ADME, Cox N, Hampson AW (Eds). Excerpta Medica, Amsterdam, Holland 939-943 (2001).
45. Piedra PA, Gaglani MJ, Kozinetz C, Glezen WP. Indirect effectiveness (herd immunity) from intranasal cold-adapted influenza vaccine - trivalent (CAIV-T) given to children 1.5 to 18 years of age, 1998-2001. Fifth Annual Conference on Vaccine Research, MD, USA (2002).
46. Piedra PA. Safety of the trivalent, cold-adpated influenza vaccine (CAIV-T) in children. Semin. Pediatr. Infect. Dis. 13, 90-96 (2002).
47. Piedra PA, Yan L, Kotloff K et al. Safety of the trivalent, cold-adapted influenza vaccine in preschool-aged children. Pediatrics 110, 662-672 (2002).
48. Bergen R, Black S, Shinefield H et al. Safety of cold-adapted live attenuated vaccine in a large cohort of children and adolescents. Pediatr. Infect. Dis. J. 23, 138-144 (2004).
49. Martinez FD, Wright AL, Taussig LM et al. Asthma and wheezing in the first six years of life. N. Engl. J. Med. 332, 133-138 (1995).